NASDAQ:AMIX Autonomix Medical Q1 2027 Earnings Results & Report $1.70 +0.18 (+11.84%) Closing price 04:00 PM EasternExtended Trading$2.13 +0.43 (+25.18%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Autonomix Medical beat analyst earnings expectations in its Q1 2027 results, released August 12, 2026. The company reported EPS of -$5.02 versus the -$6.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateAugust 12, 2026TimeBefore Market OpensConference Call DateAugust 13, 2026Conference Call7:00 AM ET Autonomix Medical EPS ResultsActual EPS-$5.02Consensus EPS -$6.40Beat/MissBeat by +$1.38One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersAutonomix Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAutonomix Medical's Q2 2027 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 16, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Autonomix Medical Q1 2027 Earnings FAQ Did Autonomix Medical beat earnings estimates for Q1 2027? Autonomix Medical (NASDAQ:AMIX) reported earnings of -$5.02 per share for Q1 2027, beating the consensus estimate of -$6.40. The report was announced on Wednesday, August 12, 2026. When is Autonomix Medical's next earnings date? Autonomix Medical's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Autonomix Medical on the company's earnings history page. Autonomix Medical Earnings HeadlinesAutonomix Medical consensus price target lowered by 30.61% to $41.62October 22, 2026 | msn.comAutonomix Medical, Inc. (AMIX) Receives a Buy from Maxim GroupOctober 18, 2026 | theglobeandmail.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 9 at 1:00 AM | Porter & Company (Ad)Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural ValidationOctober 2, 2026 | globenewswire.comAutonomix Medical Completes FDA Pre-Submission Meeting On Standalone Transvascular Sensing PlatformSeptember 30, 2026 | rttnews.comAutonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. ClearanceSeptember 30, 2026 | globenewswire.comSee More Autonomix Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Autonomix Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Autonomix Medical and other key companies, straight to your email. Email Address About Autonomix MedicalAutonomix Medical (NASDAQ:AMIX) is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures. Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures. The platform may also have applications in other conditions involving abnormal nerve activity, including certain cardiovascular and neurological disorders. The company is headquartered in The Woodlands, Texas, and its technology remains in the development and clinical evaluation stage. Autonomix Medical’s common stock trades on the Nasdaq Capital Market under the symbol AMIX.View Autonomix Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 Results Upcoming Earnings Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
